IRCT20230806059052N1 IRCT 2023-09-18 Bagheiat-allah University of Medical Sciences Safety evaluation ofstem cells in multiple sclerosis patients Safety evaluation of umbilical cord derived mesenchymal stem cells in multiple sclerosis patients 2023-08-23 anticipated 5 Complete https://irct.ir/trial/71954 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 1 Multiple sclerosis. Intervention group: The tests before the injection are performed on an outpatient basis and the patient is admitted to the hospital on the day of the injection, and the patient will be hospitalized for 24 hours after the injection. Mesenchymal stem cells will be injected at about 1x106 MSC/Kg, which is as follows: Mesenchymal stem cells will be delivered in 10 cc of normal saline and 5% albumin solution and will be injected over a period of 6 hours. Before injection, it will be in the room for 20 minutes to reach the ambient temperature. We will gently shake the solution until the cells are homogenized, remove the cells with a 10 cc syringe and inject 100 to 200 cc of normal saline serum. The serum is infused into the patient's vein within 20 minutes. Patients receive 5000 units of heparin before and after cell injection.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is اطلاعات شخصی شرکت کنندگنندگان